HomeCompareYRBAF vs MRK

YRBAF vs MRK: Dividend Comparison 2026

YRBAF yields 4434.59% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YRBAF wins by $19435683491824.89M in total portfolio value
10 years
YRBAF
YRBAF
● Live price
4434.59%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19435683491824.94M
Annual income
$18,610,150,911,100,690,000.00
Full YRBAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — YRBAF vs MRK

📍 YRBAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYRBAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YRBAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YRBAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YRBAF
Annual income on $10K today (after 15% tax)
$376,940.13/yr
After 10yr DRIP, annual income (after tax)
$15,818,628,274,435,586,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, YRBAF beats the other by $15,818,628,274,435,578,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YRBAF + MRK for your $10,000?

YRBAF: 50%MRK: 50%
100% MRK50/50100% YRBAF
Portfolio after 10yr
$9717841745912.50M
Annual income
$9,305,075,455,550,350,000.00/yr
Blended yield
95.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

YRBAF
No analyst data
Altman Z
286.7
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YRBAF buys
0
MRK buys
0
No recent congressional trades found for YRBAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYRBAFMRK
Forward yield4434.59%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$19435683491824.94M$56.8K
Annual income after 10y$18,610,150,911,100,690,000.00$9,798.13
Total dividends collected$19379595084827.07M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YRBAF vs MRK ($10,000, DRIP)

YearYRBAF PortfolioYRBAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$454,159$443,458.98$11,206$366.19+$443.0KYRBAF
2$19,308,462$18,822,511.97$12,650$502.35+$19.30MYRBAF
3$768,542,917$747,882,863.06$14,407$694.19+$768.53MYRBAF
4$28,643,181,358$27,820,840,436.44$16,585$967.82+$28643.16MYRBAF
5$999,683,499,660$969,035,295,607.07$19,342$1,363.89+$999683.48MYRBAF
6$32,677,666,626,927$31,608,005,282,290.62$22,913$1,947.19+$32677666.60MYRBAF
7$1,000,575,260,688,650$965,610,157,397,838.10$27,662$2,823.89+$1000575260.66MYRBAF
8$28,702,898,692,128,170$27,632,283,163,191,310.00$34,159$4,173.35+$28702898692.09MYRBAF
9$771,525,776,377,806,500$740,813,674,777,229,400.00$43,337$6,308.80+$771525776377.76MYRBAF
10$19,435,683,491,824,943,000$18,610,150,911,100,690,000.00$56,776$9,798.13+$19435683491824.89MYRBAF

YRBAF vs MRK: Complete Analysis 2026

YRBAFStock

Yorbeau Resources Inc. engages in the acquisition, exploration, and development of mineral properties in Canada. It explores for gold, silver, copper, zinc, and other base metals. The company holds 100% interests in the Rouyn property that consists of 1 mining concession and 94 claims having a total area of 2,684.88 hectares (ha) located in the south of Rouyn-Noranda, Québec; the Scott Lake property comprises three non-contiguous claim blocks consisting of 123 complete or partial claim cells covering an area of approximately 6,089 ha located in the townships of Lévy, Scott, and Obalski in northwestern Québec; and the Estrades-Caribou property, which consists of three contiguous claim blocks totaling 118 claims located in the Estrées Township in Québec. It also owns 100% interests in the Beschefer property that comprises 128 claims located in the Beschefer Township of northwestern Quebec; the Selbaie West property consists of 105 claims located in the Carheil and Brouillan townships in Québec; the Landrienne property, which consists of 59 claims located in the Landrienne Township in Québec; the Lemoine property comprising 102 claims located in the Lemoine, Rinfret, and Dollier townships in Québec; and the Castagnier property. In addition, the company holds interests in the Joutel-Explo Zinc project consisting of 118 claims and 1 mining concession; the Gemini-Turgeon projects comprises 189 claims; and the Allard property, which includes 43 claims located in the Abitibi region of Québec. Yorbeau Resources Inc. was incorporated in 1984 and is headquartered in Montreal, Canada.

Full YRBAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this YRBAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YRBAF vs SCHDYRBAF vs JEPIYRBAF vs OYRBAF vs KOYRBAF vs MAINYRBAF vs JNJYRBAF vs ABBVYRBAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.